镓-68 成纤维细胞活化蛋白抑制剂正电子发射断层扫描在心血管疾病中的应用
Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease.
作者信息
Mpanya Dineo, Sathekge Mike, Klug Eric, Damelin Jenna, More Stuart, Hadebe Bawinile, Vorster Mariza, Tsabedze Nqoba
机构信息
Division of Cardiology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Nuclear Medicine, University of Pretoria, Pretoria, Gauteng, South Africa.
出版信息
Front Nucl Med. 2023 Jul 27;3:1224905. doi: 10.3389/fnume.2023.1224905. eCollection 2023.
Gallium-68 fibroblast activation protein inhibitor [(Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(F)FDG] using positron emission tomography (PET). While imaging oncology patients with [Ga]Ga-FAPI PET, incidental uptake of [Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.
镓-68成纤维细胞激活蛋白抑制剂[（镓）镓-FAPI]是一种新型放射性药物，将自身定位为恶性肿瘤患者的首选药物，正电子发射断层扫描（PET）中可与2-脱氧-2-[18F]氟-D-葡萄糖[2-（F）FDG]竞争。在用[镓]镓-FAPI PET对肿瘤患者进行成像时，已在心肌中检测到[镓]镓-FAPI的意外摄取。本综述总结了将基于FAPI的示踪剂在心肌中的可视化与潜在活动性心血管疾病相关联的原始研究。
Zotero 插件